Glaxo Group Limited

Andrew Richard Whittington

Alan Naylor

Gerard Martin Paul Giblin

William L Mitchell

Russell Michael Hagan

Keith Thomas Bunce

Mark Ladlow

Barry A Coomber

Andrew John Eatherton

Richard Howard Green

Derek Anthony Rawlings

Brian Peter Slingsby

Jennifer Margaret Doughty, Legal Representative

Andrew B McElroy

William Leonard Mitchell

The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

Pyrimidine derivatives and their use as CB2 modulators

The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. ##STR1## wherein R represents the ring A ##STR2## or 2-pyridinyl or 2-pyridinyl-N-oxide; R.sup.1 is selected from halogen atoms and C.sub.1-4 alkyl, C.sub.1-4 alkoxy, trifluoromethyl, and S(O).sub.n C.sub.1-4 alkyl groups;

Medical use for tachykinin antagonists

Growing community of inventors

Stevenage, United Kingdom

Andrew Richard Whittington